APO Research
Talk to an analyst

APO RESEARCH · REPORT

Metabotropic Glutamate Receptor 5

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Metabotropic Glutamate Receptor 5 Market Outlook and Growth Opportunities 2026

22 December 2025190 pages

Choose your research edition.

Industry ResearchMetabotropic Glutamate Receptor 5 Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Metabotropic Glutamate Receptor 5 Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Metabotropic Glutamate Receptor 5 Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Metabotropic Glutamate Receptor 5 Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Metabotropic Glutamate Receptor 5 Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Metabotropic Glutamate Receptor 5 market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Metabotropic Glutamate Receptor 5 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Metabotropic Glutamate Receptor 5 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Metabotropic Glutamate Receptor 5 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Metabotropic Glutamate Receptor 5 market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Metabotropic Glutamate Receptor 5 market include Addex Therapeutics Ltd, Aevi Genomic Medicine Inc, Bristol-Myers Squibb Company, Heptares Therapeutics Ltd, Merz Pharma GmbH & Co KgaA, Richter Gedeon Nyrt, Sumitomo Dainippon Pharma Co Ltd, Toray Industries Inc and Eli Lilly and Company, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Metabotropic Glutamate Receptor 5 market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Metabotropic Glutamate Receptor 5 and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Metabotropic Glutamate Receptor 5 sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Metabotropic Glutamate Receptor 5 market size, projected growth trends, production technologies, key applications, and end-use industries.

Metabotropic Glutamate Receptor 5 Segment by Company

Addex Therapeutics Ltd

Aevi Genomic Medicine Inc

Bristol-Myers Squibb Company

Heptares Therapeutics Ltd

Merz Pharma GmbH & Co KgaA

Richter Gedeon Nyrt

Sumitomo Dainippon Pharma Co Ltd

Toray Industries Inc

Eli Lilly and Company

Novartis AG

Johnson & Johnson

Eisai Co Ltd

Metabotropic Glutamate Receptor 5 Segment by Type

Alloswitch-1

BMS-952048

BMS-955829

Dipraglurant ER

Others

Metabotropic Glutamate Receptor 5 Segment by Application

Major Depressive Disorder

Alcohol Addiction

Alzheimer's Disease

Others

Metabotropic Glutamate Receptor 5 Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Metabotropic Glutamate Receptor 5 status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Metabotropic Glutamate Receptor 5 market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Metabotropic Glutamate Receptor 5 significant trends, drivers, influence factors in global and regions.

6. To analyze Metabotropic Glutamate Receptor 5 competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Metabotropic Glutamate Receptor 5 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Metabotropic Glutamate Receptor 5 and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Metabotropic Glutamate Receptor 5.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Metabotropic Glutamate Receptor 5 market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Metabotropic Glutamate Receptor 5 industry.

Chapter 3: Detailed analysis of Metabotropic Glutamate Receptor 5 manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Metabotropic Glutamate Receptor 5 in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Metabotropic Glutamate Receptor 5 in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Metabotropic Glutamate Receptor 5 Industry Trends Table 2. Metabotropic Glutamate Receptor 5 Industry Drivers Table 3. Metabotropic Glutamate Receptor 5 Industry Opportunities and Challenges Table 4. Metabotropic Glutamate Receptor 5 Industry Restraints Table 5. Global Metabotropic Glutamate Receptor 5 Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Metabotropic Glutamate Receptor 5 Revenue Share by Company (2021-2026) Table 7. Global Metabotropic Glutamate Receptor 5 Sales Volume by Company (k units) & (2021-2026) Table 8. Global Metabotropic Glutamate Receptor 5 Sales Volume Share by Company (2021-2026) Table 9. Global Metabotropic Glutamate Receptor 5 Average Price (US$/unit) of Company (2021-2026) Table 10. Global Metabotropic Glutamate Receptor 5 Company Ranking, (2024-2026) & (USD Million) Table 11. Global Metabotropic Glutamate Receptor 5 Key Company Manufacturing Base & Headquarters Table 12. Global Metabotropic Glutamate Receptor 5 Company, Product Type & Application Table 13. Global Metabotropic Glutamate Receptor 5 Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Metabotropic Glutamate Receptor 5 by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Alloswitch-1 Table 18. Significant Companies of BMS-952048 Table 19. Significant Companies of BMS-955829 Table 20. Significant Companies of Dipraglurant ER Table 21. Significant Companies of Others Table 22. Global Metabotropic Glutamate Receptor 5 Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 23. Global Metabotropic Glutamate Receptor 5 Sales Volume by Type (2021-2026) & (k units) Table 24. Global Metabotropic Glutamate Receptor 5 Sales Volume by Type (2027-2032) & (k units) Table 25. Global Metabotropic Glutamate Receptor 5 Sales Volume Share by Type (2021-2026) Table 26. Global Metabotropic Glutamate Receptor 5 Sales Volume Share by Type (2027-2032) Table 27. Global Metabotropic Glutamate Receptor 5 Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Metabotropic Glutamate Receptor 5 Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Metabotropic Glutamate Receptor 5 Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Metabotropic Glutamate Receptor 5 Sales Value Share by Type (2021-2026) Table 31. Global Metabotropic Glutamate Receptor 5 Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Major Depressive Disorder Table 33. Significant Companies of Alcohol Addiction Table 34. Significant Companies of Alzheimer's Disease Table 35. Significant Companies of Others Table 36. Global Metabotropic Glutamate Receptor 5 Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 37. Global Metabotropic Glutamate Receptor 5 Sales Volume by Application (2021-2026) & (k units) Table 38. Global Metabotropic Glutamate Receptor 5 Sales Volume by Application (2027-2032) & (k units) Table 39. Global Metabotropic Glutamate Receptor 5 Sales Volume Share by Application (2021-2026) Table 40. Global Metabotropic Glutamate Receptor 5 Sales Volume Share by Application (2027-2032) Table 41. Global Metabotropic Glutamate Receptor 5 Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 42. Global Metabotropic Glutamate Receptor 5 Sales Value by Application (2021-2026) & (US$ Million) Table 43. Global Metabotropic Glutamate Receptor 5 Sales Value by Application (2027-2032) & (US$ Million) Table 44. Global Metabotropic Glutamate Receptor 5 Sales Value Share by Application (2021-2026) Table 45. Global Metabotropic Glutamate Receptor 5 Sales Value Share by Application (2027-2032) Table 46. Global Metabotropic Glutamate Receptor 5 Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 47. Global Metabotropic Glutamate Receptor 5 Sales by Region (2021-2026) & (k units) Table 48. Global Metabotropic Glutamate Receptor 5 Sales Market Share by Region (2021-2026) Table 49. Global Metabotropic Glutamate Receptor 5 Sales by Region (2027-2032) & (k units) Table 50. Global Metabotropic Glutamate Receptor 5 Sales Market Share by Region (2027-2032) Table 51. Global Metabotropic Glutamate Receptor 5 Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 52. Global Metabotropic Glutamate Receptor 5 Sales Value by Region (2021-2026) & (US$ Million) Table 53. Global Metabotropic Glutamate Receptor 5 Sales Value Share by Region (2021-2026) Table 54. Global Metabotropic Glutamate Receptor 5 Sales Value by Region (2027-2032) & (US$ Million) Table 55. Global Metabotropic Glutamate Receptor 5 Sales Value Share by Region (2027-2032) Table 56. Global Metabotropic Glutamate Receptor 5 Market Average Price (US$/unit) by Region (2021-2026) Table 57. Global Metabotropic Glutamate Receptor 5 Market Average Price (US$/unit) by Region (2027-2032) Table 58. Global Metabotropic Glutamate Receptor 5 Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 59. Global Metabotropic Glutamate Receptor 5 Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Metabotropic Glutamate Receptor 5 Sales by Country (2021-2026) & (k units) Table 61. Global Metabotropic Glutamate Receptor 5 Sales Market Share by Country (2021-2026) Table 62. Global Metabotropic Glutamate Receptor 5 Sales by Country (2027-2032) & (k units) Table 63. Global Metabotropic Glutamate Receptor 5 Sales Market Share by Country (2027-2032) Table 64. Global Metabotropic Glutamate Receptor 5 Sales Value by Country (2021-2026) & (US$ Million) Table 65. Global Metabotropic Glutamate Receptor 5 Sales Value Market Share by Country (2021-2026) Table 66. Global Metabotropic Glutamate Receptor 5 Sales Value by Country (2027-2032) & (US$ Million) Table 67. Global Metabotropic Glutamate Receptor 5 Sales Value Market Share by Country (2027-2032) Table 68. Addex Therapeutics Ltd Company Information Table 69. Addex Therapeutics Ltd Business Overview Table 70. Addex Therapeutics Ltd Metabotropic Glutamate Receptor 5 Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Addex Therapeutics Ltd Metabotropic Glutamate Receptor 5 Product Portfolio Table 72. Addex Therapeutics Ltd Recent Development Table 73. Aevi Genomic Medicine Inc Company Information Table 74. Aevi Genomic Medicine Inc Business Overview Table 75. Aevi Genomic Medicine Inc Metabotropic Glutamate Receptor 5 Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Aevi Genomic Medicine Inc Metabotropic Glutamate Receptor 5 Product Portfolio Table 77. Aevi Genomic Medicine Inc Recent Development Table 78. Bristol-Myers Squibb Company Company Information Table 79. Bristol-Myers Squibb Company Business Overview Table 80. Bristol-Myers Squibb Company Metabotropic Glutamate Receptor 5 Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Bristol-Myers Squibb Company Metabotropic Glutamate Receptor 5 Product Portfolio Table 82. Bristol-Myers Squibb Company Recent Development Table 83. Heptares Therapeutics Ltd Company Information Table 84. Heptares Therapeutics Ltd Business Overview Table 85. Heptares Therapeutics Ltd Metabotropic Glutamate Receptor 5 Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Heptares Therapeutics Ltd Metabotropic Glutamate Receptor 5 Product Portfolio Table 87. Heptares Therapeutics Ltd Recent Development Table 88. Merz Pharma GmbH & Co KgaA Company Information Table 89. Merz Pharma GmbH & Co KgaA Business Overview Table 90. Merz Pharma GmbH & Co KgaA Metabotropic Glutamate Receptor 5 Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Merz Pharma GmbH & Co KgaA Metabotropic Glutamate Receptor 5 Product Portfolio Table 92. Merz Pharma GmbH & Co KgaA Recent Development Table 93. Richter Gedeon Nyrt Company Information Table 94. Richter Gedeon Nyrt Business Overview Table 95. Richter Gedeon Nyrt Metabotropic Glutamate Receptor 5 Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. Richter Gedeon Nyrt Metabotropic Glutamate Receptor 5 Product Portfolio Table 97. Richter Gedeon Nyrt Recent Development Table 98. Sumitomo Dainippon Pharma Co Ltd Company Information Table 99. Sumitomo Dainippon Pharma Co Ltd Business Overview Table 100. Sumitomo Dainippon Pharma Co Ltd Metabotropic Glutamate Receptor 5 Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. Sumitomo Dainippon Pharma Co Ltd Metabotropic Glutamate Receptor 5 Product Portfolio Table 102. Sumitomo Dainippon Pharma Co Ltd Recent Development Table 103. Toray Industries Inc Company Information Table 104. Toray Industries Inc Business Overview Table 105. Toray Industries Inc Metabotropic Glutamate Receptor 5 Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 106. Toray Industries Inc Metabotropic Glutamate Receptor 5 Product Portfolio Table 107. Toray Industries Inc Recent Development Table 108. Eli Lilly and Company Company Information Table 109. Eli Lilly and Company Business Overview Table 110. Eli Lilly and Company Metabotropic Glutamate Receptor 5 Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 111. Eli Lilly and Company Metabotropic Glutamate Receptor 5 Product Portfolio Table 112. Eli Lilly and Company Recent Development Table 113. Novartis AG Company Information Table 114. Novartis AG Business Overview Table 115. Novartis AG Metabotropic Glutamate Receptor 5 Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 116. Novartis AG Metabotropic Glutamate Receptor 5 Product Portfolio Table 117. Novartis AG Recent Development Table 118. Johnson & Johnson Company Information Table 119. Johnson & Johnson Business Overview Table 120. Johnson & Johnson Metabotropic Glutamate Receptor 5 Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 121. Johnson & Johnson Metabotropic Glutamate Receptor 5 Product Portfolio Table 122. Johnson & Johnson Recent Development Table 123. Eisai Co Ltd Company Information Table 124. Eisai Co Ltd Business Overview Table 125. Eisai Co Ltd Metabotropic Glutamate Receptor 5 Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 126. Eisai Co Ltd Metabotropic Glutamate Receptor 5 Product Portfolio Table 127. Eisai Co Ltd Recent Development Table 128. Key Raw Materials Table 129. Raw Materials Key Suppliers Table 130. Metabotropic Glutamate Receptor 5 Distributors List Table 131. Metabotropic Glutamate Receptor 5 Customers List Table 132. Research Programs/Design for This Report Table 133. Authors List of This Report Table 134. Secondary Sources Table 135. Primary Sources List of Figures Figure 1. Metabotropic Glutamate Receptor 5 Product Image Figure 2. Global Metabotropic Glutamate Receptor 5 Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Metabotropic Glutamate Receptor 5 Sales Value (2021-2032) & (US$ Million) Figure 4. Global Metabotropic Glutamate Receptor 5 Sales (2021-2032) & (k units) Figure 5. Global Metabotropic Glutamate Receptor 5 Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Metabotropic Glutamate Receptor 5 Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Alloswitch-1 Image Figure 10. BMS-952048 Image Figure 11. BMS-955829 Image Figure 12. Dipraglurant ER Image Figure 13. Others Image Figure 14. Global Metabotropic Glutamate Receptor 5 Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 15. Global Metabotropic Glutamate Receptor 5 Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Metabotropic Glutamate Receptor 5 Sales Volume Share by Type (2021-2032) Figure 17. Global Metabotropic Glutamate Receptor 5 Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Metabotropic Glutamate Receptor 5 Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Metabotropic Glutamate Receptor 5 Sales Value Share by Type (2021-2032) Figure 20. Major Depressive Disorder Image Figure 21. Alcohol Addiction Image Figure 22. Alzheimer's Disease Image Figure 23. Others Image Figure 24. Global Metabotropic Glutamate Receptor 5 Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 25. Global Metabotropic Glutamate Receptor 5 Sales Volume Share 2021 VS 2025 VS 2032 Figure 26. Global Metabotropic Glutamate Receptor 5 Sales Volume Share by Application (2021-2032) Figure 27. Global Metabotropic Glutamate Receptor 5 Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Metabotropic Glutamate Receptor 5 Sales Value Share 2021 VS 2025 VS 2032 Figure 29. Global Metabotropic Glutamate Receptor 5 Sales Value Share by Application (2021-2032) Figure 30. Global Metabotropic Glutamate Receptor 5 Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 31. Global Metabotropic Glutamate Receptor 5 Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 32. Global Metabotropic Glutamate Receptor 5 Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 33. Global Metabotropic Glutamate Receptor 5 Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 34. North America Metabotropic Glutamate Receptor 5 Sales Value (2021-2032) & (US$ Million) Figure 35. North America Metabotropic Glutamate Receptor 5 Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Europe Metabotropic Glutamate Receptor 5 Sales Value (2021-2032) & (US$ Million) Figure 37. Europe Metabotropic Glutamate Receptor 5 Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Asia-Pacific Metabotropic Glutamate Receptor 5 Sales Value (2021-2032) & (US$ Million) Figure 39. Asia-Pacific Metabotropic Glutamate Receptor 5 Sales Value Share by Country (%), 2025 VS 2032 Figure 40. South America Metabotropic Glutamate Receptor 5 Sales Value (2021-2032) & (US$ Million) Figure 41. South America Metabotropic Glutamate Receptor 5 Sales Value Share by Country (%), 2025 VS 2032 Figure 42. Middle East & Africa Metabotropic Glutamate Receptor 5 Sales Value (2021-2032) & (US$ Million) Figure 43. Middle East & Africa Metabotropic Glutamate Receptor 5 Sales Value Share by Country (%), 2025 VS 2032 Figure 44. USA Metabotropic Glutamate Receptor 5 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. USA Metabotropic Glutamate Receptor 5 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. USA Metabotropic Glutamate Receptor 5 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Canada Metabotropic Glutamate Receptor 5 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Canada Metabotropic Glutamate Receptor 5 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Canada Metabotropic Glutamate Receptor 5 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Mexico Metabotropic Glutamate Receptor 5 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Mexico Metabotropic Glutamate Receptor 5 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Mexico Metabotropic Glutamate Receptor 5 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Germany Metabotropic Glutamate Receptor 5 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Germany Metabotropic Glutamate Receptor 5 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Germany Metabotropic Glutamate Receptor 5 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. France Metabotropic Glutamate Receptor 5 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. France Metabotropic Glutamate Receptor 5 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. France Metabotropic Glutamate Receptor 5 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. U.K. Metabotropic Glutamate Receptor 5 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. U.K. Metabotropic Glutamate Receptor 5 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. U.K. Metabotropic Glutamate Receptor 5 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Italy Metabotropic Glutamate Receptor 5 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Italy Metabotropic Glutamate Receptor 5 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Italy Metabotropic Glutamate Receptor 5 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Spain Metabotropic Glutamate Receptor 5 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Spain Metabotropic Glutamate Receptor 5 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Spain Metabotropic Glutamate Receptor 5 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Russia Metabotropic Glutamate Receptor 5 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Russia Metabotropic Glutamate Receptor 5 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Russia Metabotropic Glutamate Receptor 5 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Netherlands Metabotropic Glutamate Receptor 5 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Netherlands Metabotropic Glutamate Receptor 5 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Netherlands Metabotropic Glutamate Receptor 5 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Nordic Countries Metabotropic Glutamate Receptor 5 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Nordic Countries Metabotropic Glutamate Receptor 5 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Nordic Countries Metabotropic Glutamate Receptor 5 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. China Metabotropic Glutamate Receptor 5 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. China Metabotropic Glutamate Receptor 5 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. China Metabotropic Glutamate Receptor 5 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Japan Metabotropic Glutamate Receptor 5 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Japan Metabotropic Glutamate Receptor 5 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Japan Metabotropic Glutamate Receptor 5 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. South Korea Metabotropic Glutamate Receptor 5 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. South Korea Metabotropic Glutamate Receptor 5 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. South Korea Metabotropic Glutamate Receptor 5 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. India Metabotropic Glutamate Receptor 5 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. India Metabotropic Glutamate Receptor 5 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. India Metabotropic Glutamate Receptor 5 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Australia Metabotropic Glutamate Receptor 5 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Australia Metabotropic Glutamate Receptor 5 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Australia Metabotropic Glutamate Receptor 5 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Southeast Asia Metabotropic Glutamate Receptor 5 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Southeast Asia Metabotropic Glutamate Receptor 5 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Southeast Asia Metabotropic Glutamate Receptor 5 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Brazil Metabotropic Glutamate Receptor 5 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Brazil Metabotropic Glutamate Receptor 5 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Brazil Metabotropic Glutamate Receptor 5 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Argentina Metabotropic Glutamate Receptor 5 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Argentina Metabotropic Glutamate Receptor 5 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Argentina Metabotropic Glutamate Receptor 5 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Chile Metabotropic Glutamate Receptor 5 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Chile Metabotropic Glutamate Receptor 5 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Chile Metabotropic Glutamate Receptor 5 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Colombia Metabotropic Glutamate Receptor 5 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Colombia Metabotropic Glutamate Receptor 5 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Colombia Metabotropic Glutamate Receptor 5 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Peru Metabotropic Glutamate Receptor 5 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Peru Metabotropic Glutamate Receptor 5 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Peru Metabotropic Glutamate Receptor 5 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Metabotropic Glutamate Receptor 5 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Saudi Arabia Metabotropic Glutamate Receptor 5 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Metabotropic Glutamate Receptor 5 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Israel Metabotropic Glutamate Receptor 5 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Israel Arabia Metabotropic Glutamate Receptor 5 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Israel Arabia Metabotropic Glutamate Receptor 5 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. UAE Metabotropic Glutamate Receptor 5 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. UAE Metabotropic Glutamate Receptor 5 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. UAE Metabotropic Glutamate Receptor 5 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Turkey Metabotropic Glutamate Receptor 5 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Turkey Metabotropic Glutamate Receptor 5 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Turkey Metabotropic Glutamate Receptor 5 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Iran Metabotropic Glutamate Receptor 5 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Iran Metabotropic Glutamate Receptor 5 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Iran Metabotropic Glutamate Receptor 5 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Egypt Metabotropic Glutamate Receptor 5 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 126. Egypt Metabotropic Glutamate Receptor 5 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 127. Egypt Metabotropic Glutamate Receptor 5 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 128. Metabotropic Glutamate Receptor 5 Value Chain Figure 129. Manufacturing Cost Structure Figure 130. Metabotropic Glutamate Receptor 5 Sales Mode & Process Figure 131. Direct Comparison with Distribution Share Figure 132. Distributors Profiles Figure 133. Years Considered Figure 134. Research Process Figure 135. Key Executives Interviewed

Scope & coverage.

Types
  • Alloswitch-1
  • BMS-952048
  • BMS-955829
  • Dipraglurant ER
  • Others
Applications
  • Major Depressive Disorder
  • Alcohol Addiction
  • Alzheimer's Disease
  • Others
Companies covered
  • Addex Therapeutics Ltd
  • Aevi Genomic Medicine Inc
  • Bristol-Myers Squibb Company
  • Heptares Therapeutics Ltd
  • Merz Pharma GmbH & Co KgaA
  • Richter Gedeon Nyrt
  • Sumitomo Dainippon Pharma Co Ltd
  • Toray Industries Inc
  • Eli Lilly and Company
  • Novartis AG
  • Johnson & Johnson
  • Eisai Co Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Metabotropic Glutamate Receptor 5 Sales Value (2021-2032)
  4. 1.2.2 Global Metabotropic Glutamate Receptor 5 Sales Volume (2021-2032)
  5. 1.2.3 Global Metabotropic Glutamate Receptor 5 Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Metabotropic Glutamate Receptor 5 Market Dynamics
  1. 2.1 Metabotropic Glutamate Receptor 5 Industry Trends
  2. 2.2 Metabotropic Glutamate Receptor 5 Industry Drivers
  3. 2.3 Metabotropic Glutamate Receptor 5 Industry Opportunities and Challenges
  4. 2.4 Metabotropic Glutamate Receptor 5 Industry Restraints
3 Metabotropic Glutamate Receptor 5 Market by Company
  1. 3.1 Global Metabotropic Glutamate Receptor 5 Company Revenue Ranking in 2025
  2. 3.2 Global Metabotropic Glutamate Receptor 5 Revenue by Company (2021-2026)
  3. 3.3 Global Metabotropic Glutamate Receptor 5 Sales Volume by Company (2021-2026)
  4. 3.4 Global Metabotropic Glutamate Receptor 5 Average Price by Company (2021-2026)
  5. 3.5 Global Metabotropic Glutamate Receptor 5 Company Ranking (2024-2026)
  6. 3.6 Global Metabotropic Glutamate Receptor 5 Company Manufacturing Base and Headquarters
  7. 3.7 Global Metabotropic Glutamate Receptor 5 Company Product Type and Application
  8. 3.8 Global Metabotropic Glutamate Receptor 5 Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Metabotropic Glutamate Receptor 5 Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Metabotropic Glutamate Receptor 5 Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Metabotropic Glutamate Receptor 5 Market by Type
  1. 4.1 Metabotropic Glutamate Receptor 5 Type Introduction
  2. 4.1.1 Alloswitch-1
  3. 4.1.2 BMS-952048
  4. 4.1.3 BMS-955829
  5. 4.1.4 Dipraglurant ER
  6. 4.1.5 Others
  7. 4.2 Global Metabotropic Glutamate Receptor 5 Sales Volume by Type
  8. 4.2.1 Global Metabotropic Glutamate Receptor 5 Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Metabotropic Glutamate Receptor 5 Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Metabotropic Glutamate Receptor 5 Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Metabotropic Glutamate Receptor 5 Sales Value by Type
  12. 4.3.1 Global Metabotropic Glutamate Receptor 5 Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Metabotropic Glutamate Receptor 5 Sales Value by Type (2021-2032)
  14. 4.3.3 Global Metabotropic Glutamate Receptor 5 Sales Value Share by Type (2021-2032)
5 Metabotropic Glutamate Receptor 5 Market by Application
  1. 5.1 Metabotropic Glutamate Receptor 5 Application Introduction
  2. 5.1.1 Major Depressive Disorder
  3. 5.1.2 Alcohol Addiction
  4. 5.1.3 Alzheimer's Disease
  5. 5.1.4 Others
  6. 5.2 Global Metabotropic Glutamate Receptor 5 Sales Volume by Application
  7. 5.2.1 Global Metabotropic Glutamate Receptor 5 Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Metabotropic Glutamate Receptor 5 Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Metabotropic Glutamate Receptor 5 Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Metabotropic Glutamate Receptor 5 Sales Value by Application
  11. 5.3.1 Global Metabotropic Glutamate Receptor 5 Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Metabotropic Glutamate Receptor 5 Sales Value by Application (2021-2032)
  13. 5.3.3 Global Metabotropic Glutamate Receptor 5 Sales Value Share by Application (2021-2032)
6 Metabotropic Glutamate Receptor 5 Regional Sales and Value Analysis
  1. 6.1 Global Metabotropic Glutamate Receptor 5 Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Metabotropic Glutamate Receptor 5 Sales by Region (2021-2032)
  3. 6.2.1 Global Metabotropic Glutamate Receptor 5 Sales by Region: 2021-2026
  4. 6.2.2 Global Metabotropic Glutamate Receptor 5 Sales by Region (2027-2032)
  5. 6.3 Global Metabotropic Glutamate Receptor 5 Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Metabotropic Glutamate Receptor 5 Sales Value by Region (2021-2032)
  7. 6.4.1 Global Metabotropic Glutamate Receptor 5 Sales Value by Region: 2021-2026
  8. 6.4.2 Global Metabotropic Glutamate Receptor 5 Sales Value by Region (2027-2032)
  9. 6.5 Global Metabotropic Glutamate Receptor 5 Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Metabotropic Glutamate Receptor 5 Sales Value (2021-2032)
  12. 6.6.2 North America Metabotropic Glutamate Receptor 5 Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Metabotropic Glutamate Receptor 5 Sales Value (2021-2032)
  15. 6.7.2 Europe Metabotropic Glutamate Receptor 5 Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Metabotropic Glutamate Receptor 5 Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Metabotropic Glutamate Receptor 5 Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Metabotropic Glutamate Receptor 5 Sales Value (2021-2032)
  21. 6.9.2 South America Metabotropic Glutamate Receptor 5 Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Metabotropic Glutamate Receptor 5 Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Metabotropic Glutamate Receptor 5 Sales Value Share by Country, 2025 VS 2032
7 Metabotropic Glutamate Receptor 5 Country-level Sales and Value Analysis
  1. 7.1 Global Metabotropic Glutamate Receptor 5 Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Metabotropic Glutamate Receptor 5 Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Metabotropic Glutamate Receptor 5 Sales by Country (2021-2032)
  4. 7.3.1 Global Metabotropic Glutamate Receptor 5 Sales by Country (2021-2026)
  5. 7.3.2 Global Metabotropic Glutamate Receptor 5 Sales by Country (2027-2032)
  6. 7.4 Global Metabotropic Glutamate Receptor 5 Sales Value by Country (2021-2032)
  7. 7.4.1 Global Metabotropic Glutamate Receptor 5 Sales Value by Country (2021-2026)
  8. 7.4.2 Global Metabotropic Glutamate Receptor 5 Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Metabotropic Glutamate Receptor 5 Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Metabotropic Glutamate Receptor 5 Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Metabotropic Glutamate Receptor 5 Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Metabotropic Glutamate Receptor 5 Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Metabotropic Glutamate Receptor 5 Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Metabotropic Glutamate Receptor 5 Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Metabotropic Glutamate Receptor 5 Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Metabotropic Glutamate Receptor 5 Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Metabotropic Glutamate Receptor 5 Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Metabotropic Glutamate Receptor 5 Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Metabotropic Glutamate Receptor 5 Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Metabotropic Glutamate Receptor 5 Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Metabotropic Glutamate Receptor 5 Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Metabotropic Glutamate Receptor 5 Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Metabotropic Glutamate Receptor 5 Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Metabotropic Glutamate Receptor 5 Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Metabotropic Glutamate Receptor 5 Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Metabotropic Glutamate Receptor 5 Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Metabotropic Glutamate Receptor 5 Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Metabotropic Glutamate Receptor 5 Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Metabotropic Glutamate Receptor 5 Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Metabotropic Glutamate Receptor 5 Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Metabotropic Glutamate Receptor 5 Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Metabotropic Glutamate Receptor 5 Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Metabotropic Glutamate Receptor 5 Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Metabotropic Glutamate Receptor 5 Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Metabotropic Glutamate Receptor 5 Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Metabotropic Glutamate Receptor 5 Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Metabotropic Glutamate Receptor 5 Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Metabotropic Glutamate Receptor 5 Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Metabotropic Glutamate Receptor 5 Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Metabotropic Glutamate Receptor 5 Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Metabotropic Glutamate Receptor 5 Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Metabotropic Glutamate Receptor 5 Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Metabotropic Glutamate Receptor 5 Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Metabotropic Glutamate Receptor 5 Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Metabotropic Glutamate Receptor 5 Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Metabotropic Glutamate Receptor 5 Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Metabotropic Glutamate Receptor 5 Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Metabotropic Glutamate Receptor 5 Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Metabotropic Glutamate Receptor 5 Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Metabotropic Glutamate Receptor 5 Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Metabotropic Glutamate Receptor 5 Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Metabotropic Glutamate Receptor 5 Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Metabotropic Glutamate Receptor 5 Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Metabotropic Glutamate Receptor 5 Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Metabotropic Glutamate Receptor 5 Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Metabotropic Glutamate Receptor 5 Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Metabotropic Glutamate Receptor 5 Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Metabotropic Glutamate Receptor 5 Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Metabotropic Glutamate Receptor 5 Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Metabotropic Glutamate Receptor 5 Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Metabotropic Glutamate Receptor 5 Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Metabotropic Glutamate Receptor 5 Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Metabotropic Glutamate Receptor 5 Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Metabotropic Glutamate Receptor 5 Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Metabotropic Glutamate Receptor 5 Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Metabotropic Glutamate Receptor 5 Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Metabotropic Glutamate Receptor 5 Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Metabotropic Glutamate Receptor 5 Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Metabotropic Glutamate Receptor 5 Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Metabotropic Glutamate Receptor 5 Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Metabotropic Glutamate Receptor 5 Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Metabotropic Glutamate Receptor 5 Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Metabotropic Glutamate Receptor 5 Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Metabotropic Glutamate Receptor 5 Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Metabotropic Glutamate Receptor 5 Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Metabotropic Glutamate Receptor 5 Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Metabotropic Glutamate Receptor 5 Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Metabotropic Glutamate Receptor 5 Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Metabotropic Glutamate Receptor 5 Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Metabotropic Glutamate Receptor 5 Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Metabotropic Glutamate Receptor 5 Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Metabotropic Glutamate Receptor 5 Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Metabotropic Glutamate Receptor 5 Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Metabotropic Glutamate Receptor 5 Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Metabotropic Glutamate Receptor 5 Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Metabotropic Glutamate Receptor 5 Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Metabotropic Glutamate Receptor 5 Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Metabotropic Glutamate Receptor 5 Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Metabotropic Glutamate Receptor 5 Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Metabotropic Glutamate Receptor 5 Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Metabotropic Glutamate Receptor 5 Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Metabotropic Glutamate Receptor 5 Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Addex Therapeutics Ltd
  2. 8.1.1 Addex Therapeutics Ltd Company Information
  3. 8.1.2 Addex Therapeutics Ltd Business Overview
  4. 8.1.3 Addex Therapeutics Ltd Metabotropic Glutamate Receptor 5 Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Addex Therapeutics Ltd Metabotropic Glutamate Receptor 5 Product Portfolio
  6. 8.1.5 Addex Therapeutics Ltd Recent Developments
  7. 8.2 Aevi Genomic Medicine Inc
  8. 8.2.1 Aevi Genomic Medicine Inc Company Information
  9. 8.2.2 Aevi Genomic Medicine Inc Business Overview
  10. 8.2.3 Aevi Genomic Medicine Inc Metabotropic Glutamate Receptor 5 Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Aevi Genomic Medicine Inc Metabotropic Glutamate Receptor 5 Product Portfolio
  12. 8.2.5 Aevi Genomic Medicine Inc Recent Developments
  13. 8.3 Bristol-Myers Squibb Company
  14. 8.3.1 Bristol-Myers Squibb Company Company Information
  15. 8.3.2 Bristol-Myers Squibb Company Business Overview
  16. 8.3.3 Bristol-Myers Squibb Company Metabotropic Glutamate Receptor 5 Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Bristol-Myers Squibb Company Metabotropic Glutamate Receptor 5 Product Portfolio
  18. 8.3.5 Bristol-Myers Squibb Company Recent Developments
  19. 8.4 Heptares Therapeutics Ltd
  20. 8.4.1 Heptares Therapeutics Ltd Company Information
  21. 8.4.2 Heptares Therapeutics Ltd Business Overview
  22. 8.4.3 Heptares Therapeutics Ltd Metabotropic Glutamate Receptor 5 Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Heptares Therapeutics Ltd Metabotropic Glutamate Receptor 5 Product Portfolio
  24. 8.4.5 Heptares Therapeutics Ltd Recent Developments
  25. 8.5 Merz Pharma GmbH & Co KgaA
  26. 8.5.1 Merz Pharma GmbH & Co KgaA Company Information
  27. 8.5.2 Merz Pharma GmbH & Co KgaA Business Overview
  28. 8.5.3 Merz Pharma GmbH & Co KgaA Metabotropic Glutamate Receptor 5 Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Merz Pharma GmbH & Co KgaA Metabotropic Glutamate Receptor 5 Product Portfolio
  30. 8.5.5 Merz Pharma GmbH & Co KgaA Recent Developments
  31. 8.6 Richter Gedeon Nyrt
  32. 8.6.1 Richter Gedeon Nyrt Company Information
  33. 8.6.2 Richter Gedeon Nyrt Business Overview
  34. 8.6.3 Richter Gedeon Nyrt Metabotropic Glutamate Receptor 5 Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Richter Gedeon Nyrt Metabotropic Glutamate Receptor 5 Product Portfolio
  36. 8.6.5 Richter Gedeon Nyrt Recent Developments
  37. 8.7 Sumitomo Dainippon Pharma Co Ltd
  38. 8.7.1 Sumitomo Dainippon Pharma Co Ltd Company Information
  39. 8.7.2 Sumitomo Dainippon Pharma Co Ltd Business Overview
  40. 8.7.3 Sumitomo Dainippon Pharma Co Ltd Metabotropic Glutamate Receptor 5 Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Sumitomo Dainippon Pharma Co Ltd Metabotropic Glutamate Receptor 5 Product Portfolio
  42. 8.7.5 Sumitomo Dainippon Pharma Co Ltd Recent Developments
  43. 8.8 Toray Industries Inc
  44. 8.8.1 Toray Industries Inc Company Information
  45. 8.8.2 Toray Industries Inc Business Overview
  46. 8.8.3 Toray Industries Inc Metabotropic Glutamate Receptor 5 Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Toray Industries Inc Metabotropic Glutamate Receptor 5 Product Portfolio
  48. 8.8.5 Toray Industries Inc Recent Developments
  49. 8.9 Eli Lilly and Company
  50. 8.9.1 Eli Lilly and Company Company Information
  51. 8.9.2 Eli Lilly and Company Business Overview
  52. 8.9.3 Eli Lilly and Company Metabotropic Glutamate Receptor 5 Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Eli Lilly and Company Metabotropic Glutamate Receptor 5 Product Portfolio
  54. 8.9.5 Eli Lilly and Company Recent Developments
  55. 8.10 Novartis AG
  56. 8.10.1 Novartis AG Company Information
  57. 8.10.2 Novartis AG Business Overview
  58. 8.10.3 Novartis AG Metabotropic Glutamate Receptor 5 Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Novartis AG Metabotropic Glutamate Receptor 5 Product Portfolio
  60. 8.10.5 Novartis AG Recent Developments
  61. 8.11 Johnson & Johnson
  62. 8.11.1 Johnson & Johnson Company Information
  63. 8.11.2 Johnson & Johnson Business Overview
  64. 8.11.3 Johnson & Johnson Metabotropic Glutamate Receptor 5 Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Johnson & Johnson Metabotropic Glutamate Receptor 5 Product Portfolio
  66. 8.11.5 Johnson & Johnson Recent Developments
  67. 8.12 Eisai Co Ltd
  68. 8.12.1 Eisai Co Ltd Company Information
  69. 8.12.2 Eisai Co Ltd Business Overview
  70. 8.12.3 Eisai Co Ltd Metabotropic Glutamate Receptor 5 Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Eisai Co Ltd Metabotropic Glutamate Receptor 5 Product Portfolio
  72. 8.12.5 Eisai Co Ltd Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Metabotropic Glutamate Receptor 5 Value Chain Analysis
  2. 9.1.1 Metabotropic Glutamate Receptor 5 Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Metabotropic Glutamate Receptor 5 Sales Mode & Process
  6. 9.2 Metabotropic Glutamate Receptor 5 Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Metabotropic Glutamate Receptor 5 Distributors
  9. 9.2.3 Metabotropic Glutamate Receptor 5 Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst